Please provide your email address to receive an email when new articles are posted on . The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for ...

(HealthDay)—Longer duration of bisphosphonate use is associated with an increased risk for atypical femur fracture, according to a study published in the Aug. 20 issue of the New England Journal of ...

The relative risk of an atypical femoral fracture with bisphosphonate use related to duration of therapy, with the highest risks being seen after 5 years of exposure, a nationwide study in Denmark ...

The risk of atypical femur fractures increases with prolonged use of bisphosphonates, drugs commonly used to treat osteoporosis, according to a new study. The research, conducted by scientists at the ...

LAS VEGAS — Denosumab (Prolia, Amgen) use in patients with osteoporosis was not associated with increased risks for subtrochanteric and diaphyseal femur fractures compared with bisphosphonate use, ...

Please provide your email address to receive an email when new articles are posted on . Among South-East Asian adults, bisphosphonate use in is not associated with differences in clinical outcomes or ...

In about 70% of patients, pain in the thigh or groin may be present for several weeks or months before the atypical femoral fracture occurs.1 Patients receiving long-term antiresorptive treatment (e.g ...

AP X-ray of an 82 year old female with bisphosphonate related atypical transverse stress insufficiency fracture associated with focal lateral cortical thickening of subtrochanteric cortex of proximal ...

An estimated 255,000 fragility fractures occur annually in Türkiye, the equivalent of approximately 29 broken bones per hour. The cause is osteoporosis, a disease in which the skeleton becomes weak ...

(HealthDay News) — Bisphosphonate use, especially over a long duration, is associated with increased risk of atypical femoral fracture, according to a study published in the September 4 issue of the ...

Bisphosphonate use is associated with only a very low risk of atypical fractures to the subtrochanteric or diaphyseal femur, even in women who receive the drugs for up to 10 years, data from an ...